Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma

  title={Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma},
  author={Ramzi M. Mohammad and George R. Pettit and V P Almatchy and Nathan R. Wall and Mary L. Varterasian and Ayad M. Ai-Katib},
  journal={Anti-Cancer Drugs},
We studied the antitumor effects of dolastatin 10, its structural modification, auristatin PE (TZT-1027), and vincristine alone and in combination with bryostatin 1 on a human diffuse large cell lymphoma line (WSU-DLCL2) in vitro and in vivo. WSU-DLCL2 cells were cultured in RPMI 1640 at a concentration of 2 × 105/ml using a 24-well plate. Agents were added to triplicate wells, and cell count, viability, mitosis and apoptosis were assessed. Dolastatin 10 showed no apparent inhibition of cell… Expand
Induction of Apoptosis in Mice with B16 Melanoma by Treatment with the Antimicrotubule Agent TZT-1027
It is speculated that the effect on B16 melanoma cells of TZT-1027 differed with the treatment dose, and a dose of 2 mg/kg induces apoptosis in tumor cells by a direct mechanism. Expand
Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry
The biological activity and chemical work of Dol-10 in the advance of antitumor drugs in the last 35 years will be summarized, which will provide the support for pharmaceutical researchers interested in leading exploration of antitUMor marine peptides. Expand
Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models.
The mechanism of action and efficacy of a synthetic analogue, auristatin PYE, was investigated in 2 human colon adenocarcinoma models, DLD-1 and COLO 205, and it is suggested that auristarin PYE has good potential as an anti-cancer agent. Expand
TZT‐1027, an Antimicrotubule Agent, Attacks Tumor Vasculature and Induces Tumor Cell Death
TZT‐1027 quickly attacked the well‐developed vascular system of advanced tumors by a putative protein kinase‐dependent mechanism, and then blocked tumor blood flow, making it a potentially powerful tool for clinical cancer therapy. Expand
Potentiation of the activity of cisplatin in a human colon tumour xenograft model by auristatin PYE, a structural modification of dolastatin 10.
Auristatin PYE demonstrated synergistic antitumour effects when combined with cisplatin, suggesting that a combination chemotherapy regimen would be the most effective strategy when applying this new anticancer drug. Expand
Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.
Dolastatin-10 is very well tolerated in this elderly, pretreated population but lacks significant clinical activity as a single agent in patients with hormone-refractory prostate cancer. Expand
Phase II Study of Dolastatin-10 in Patients with Hormone-refractory Metastatic Prostate Adenocarcinoma 1
Dolastatin-10 is a natural, cytotoxic peptide with microtubule-inhibitory and apoptotic effects. It has demonstratedin vitro and in vivo efficacy in the DU-145 human prostate cancer model. A Phase IIExpand
Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model
It is demonstrated that bryo1 induces differentiation and potentiates the antitumor effect of AuriPE in a human pancreatic tumor (PANC-1) xenograft model in severe combined immune deficient (SCID) mice, the first report where this effect is demonstrated in pancreatic tumors. Expand
Bryostatin has proved to be a very potent antitumor-promoting agent, and a very promising anticancer drug, and it has provided curative levels of activity against a variety of murine experimental cancer systems. Expand
Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug.
  • Philip, Zonder
  • Medicine
  • Expert opinion on investigational drugs
  • 1999
There is ample in vitro data demonstrating that bryo 1 can sensitise tumour cells to cytotoxic agents, and recent clinical work has focused on combining b Bryo 1 with traditional chemotherapeutic agents for both haematologic and non-haematological cancers. Expand